2 results
Approved WMOCompleted
To evaluate and compare progression free survival (PSA) between the two treatment arms.
Approved WMORecruitment stopped
Primary Objective - To evaluate the time to PSA >4 ng/mL during the first cycle of IAD after the end of an induction period with degarelix (7 monthly treatments) in prostate cancer patientsSecondary Objectives - To evaluate the time to PSA .4…